Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study-authors' response

J Antimicrob Chemother. 2023 Jul 5;78(7):1809-1810. doi: 10.1093/jac/dkad152.

Authors

Antonella d'Arminio Monforte¹, Alessandro Tavelli¹, Andrea Antinori², Alessandro Cozzi-Lepri³

Affiliations

¹ ICONA Foundation, Milan, Italy.
² Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, ICONA Foundation, via A. di Rudinì 8, 20142, Rome, Italy.
³ Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.

PMID: 37231109
DOI: 10.1093/jac/dkad152

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter
Comment

MeSH terms

Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Oxazines / therapeutic use
Pyridones / therapeutic use

Substances

dolutegravir
Anti-HIV Agents
Oxazines
Heterocyclic Compounds, 3-Ring
Pyridones